Myriad Genetics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
8analysts covering
FY Revenue (est.)
$863.6Mnext fiscal year
FY EPS (est.)
$0.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Financial Earnings Release | 3 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly200.4MTarget: Reiterate full-year 2026 revenue guidance of $860 million to $880 million
Adjusted EBITDA Quarterly-4.5MTarget: Full-year 2026 adjusted EBITDA guidance of $37 million to $49 million
Total Test Volume Quarterly385KTarget: Sequential volume growth driven by Cancer Care Continuum and Mental Health segments
Watch Items
- Prenatal Health Segment RecoveryTrigger: Further double-digit year-over-year volume declines in prenatal testingAction: Reassess commercial execution and customer engagement strategies following the Q2 2025 order management system disruption.
- Debt Covenant ComplianceTrigger: Trailing twelve-month revenue falling below escalating credit facility covenantsAction: Evaluate refinancing options or capital restructuring for the $125.0 million term loan.
Research as of 19 Jun 2026